Email: cspc@cspc.cn
News
January 13, 2026
Share:
Previous: VOLUNTARY ANNOUNCEMENT - SYS6055 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Next: VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us